Diabetes Type 2, Obesity, Overweight, PreDiabetes
Conditions
Brief summary
This study is being done to better understand whether meal replacements can be an effective tool for weight loss and treatment of elevated blood sugars in people with obesity/overweight and diabetes/pre-diabetes who have a low income.
Detailed description
The Medically Intensive Nutritional Therapy (MINT) program at Massachusetts General Hospital (MGH) Weight Center is a low-calorie nutrition plan that may offer a solution for those who have difficulty implementing a low-calorie dietary plan on their own. This study examines the effects of MINT on weight loss and blood sugar control specifically in a low-income population and explores potential reasons for discontinuing the program.
Interventions
DIETARY_SUPPLEMENTBariatrix Meal Replacement Products
Meal replacement products offered through the Massachusetts General Hospital Weight Center.
Sponsors
Massachusetts General Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-65 * Body mass index (BMI) greater than or equal to 27 kg/m\^2 * HgA1C greater than or equal to 5.7 percent or fasting glucose greater than or equal to 100mg/dL within the previous 6 months * Low-income as defined by having a family income at or below 400 percent of the federal poverty level guidelines for 2022
Exclusion criteria
* Current use of antihyperglycemic agents (other than metformin) or approved anti- obesity medications or plans to start such regimens over the 3 months post-study enrollment * HbA1c greater than or equal to 10 percent * Plans to pursue bariatric surgery over the 6 months post-study enrollment * Weight loss of greater than 5 kg within the previous 3 months * Current active eating disorder, with the exception of binge eating disorder * Severe active psychiatric disease or significant cognitive impairment deemed by investigator likely to impede adherence to piloted intervention * Active illicit substance abuse * Pregnant, breastfeeding, or considering pregnancy within the next 6 months * Current participation in another clinical research trial deemed by investigator to conflict with current study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body weight reduction | 3 months | Reduction in body weight by greater than or equal to 5 percent |
| Hemoglobin A1c reduction | 3 months | Reduction of Hemoglobin A1c by greater than or equal to 0.5 percent |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Program adherence | 3 months | Adherence with the program, and potential reasons for non-adherence as assessed with bi-weekly questionnaires |
Countries
United States
Contacts
Primary ContactChika V Anekwe, MD
Outcome results
None listed